About Biogenomics

Science First. Ethics Always.

Biogenomics was founded to bridge the gap between world-class biotechnology research and the medical providers who need reliable access to it. With roots in Korean biotech innovation and over two decades of clinical practice and regenerative medicine research, we set out to build the supply chain that providers deserve — direct, transparent, and uncompromising on quality.

Our peptide API line extends that mission. We source exclusively from a US-based, cGMP-compliant manufacturer holding both 503A traditional compounding and 503B FDA-registered outsourcing facility licenses. Every lot is third-party tested and ships with a Certificate of Analysis. Our verified provider network's combined volume sets pricing tiers no individual practice could negotiate — passed through to your portal at registration.

This is not a marketplace. It is a curated supply chain, informed by research and built for practitioners who hold quality to the same standard we do.

Leadership

Founder & CEO

Founder bio to be added. With a personal and career connection to Korean biotech and the US-Korea medical innovation bridge, our founder built Biogenomics to deliver the quality and directness that providers expect from a research-grade API source.

[INTAKE: Professional background, personal connection to the peptide/API space, and the moment that sparked Biogenomics — details TBD in MARKETING-INTAKE.md]

503A + 503B Dual-Licensed Source

Our manufacturing partner holds both 503A traditional compounding and 503B FDA-registered outsourcing facility licenses — an uncommon dual posture for peptide API supply. In-house R&D into formulation and lyophilization technique runs continuously, with a third-party COA on every lot.

The Korea-US Bridge

Korean biotech sets a global quality bar in regenerative medicine, cell therapy, and advanced biologics. Biogenomics brings that standard to American medical providers — bridging research-grade innovation with clinical-practice reality.

Beyond Peptide APIs

The Biogenomics Platform

The peptide API line is one arm of a broader regenerative medicine platform. Biogenomics also develops and distributes:

Exosome Solutions

Exosome-based products for skin healing and rejuvenation in aesthetic medicine.

Regenerative Skincare

Ready-made and custom formulations informed by regenerative research.

Provider Education

Training programs in partnership with global aesthetic medicine leaders.

Join Our Provider Network

Registration is restricted to licensed medical providers with an active NPI number and state license.

Register Your Practice